[{"indications": "Indications\u00a0hypertension; migraine (section 4.7.4.2); menopausal flushing (section 6.4.1.1)", "name": "CLONIDINE HYDROCHLORIDE ", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.2 Centrally acting antihypertensive drugs"], "cautions": "Cautions\u00a0must be withdrawn gradually to avoid\r\nsevere rebound hypertension; mild to moderate\r\nbradyarrhythmia; constipation; polyneuropathy; Raynaud\u2019s\r\nsyndrome or other occlusive peripheral\r\nvascular disease; history of depression; interactions: Appendix 1 (clonidine)Driving\u00a0Drowsiness may affect performance\r\nof skilled tasks (e.g. driving); effects\r\nof alcohol may be enhanced", "side-effects": "Side-effects\u00a0constipation, nausea, dry mouth, vomiting, salivary\r\ngland pain, postural hypotension, dizziness, sleep disturbances, headache,\r\nmalaise, drowsiness, depression, sexual dysfunction, less\r\ncommonly bradycardia, Raynaud\u2019s syndrome, delusion, hallucination,\r\nparaesthesia, pruritus, rash, urticaria; rarely colonic\r\npseudo-obstruction, AV block, gynaecomastia, decreased lacrimation,\r\nnasal dryness, alopecia; also reported hepatitis,\r\nfluid retention, bradyarrhythmia, confusion, impaired visual accommodation", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2546.htm", "doses": ["By mouth, 50\u2013100\u00a0micrograms 3 times\r\ndaily, increased every second or third day; usual max. dose 1.2\u00a0mg\r\ndaily"], "pregnancy": "Pregnancy\u00a0may lower fetal heart rate, but risk should be balanced\r\nagainst risk of uncontrolled maternal hypertension; avoid intravenous\r\ninjection"}, {"indications": "Indications\u00a0prevention of recurrent migraine\r\n(but see notes above), vascular headache, menopausal flushing; hypertension\r\n(%s\n(From 2.5.2 Centrally acting antihypertensive drugs: British National Formulary)\n2.5.2 Centrally acting antihypertensive drugs)", "name": "CLONIDINE HYDROCHLORIDE  - PROPHYLAXIS OF MIGRAINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.4 Antimigraine drugs", "4.7.4.2 Prophylaxis of migraine", "CLONIDINE HYDROCHLORIDE"], "cautions": "Cautions\u00a0depressive illness; heart failure; Raynaud\u2019s syndrome; concurrent antihypertensive therapy; cerebrovascular disease; polyneuropathy; constipation; interactions: Appendix 1 (clonidine)", "side-effects": "Side-effects\u00a0constipation, dry mouth, nausea, vomiting; postural\r\nhypotension; depression, sleep disorder, dizziness, headache, drowsiness;\r\nerectile dysfunction; less commonly Raynaud\u2019s syndrome,\r\nparaesthesia, hallucination, rash, and pruritus; rarely AV block, gynaecomastia, and alopecia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3568.htm", "doses": ["adult over 18 years, 50\u00a0micrograms\r\ntwice daily, increased after 2 weeks to 75\u00a0micrograms twice daily\r\nif necessary"], "pregnancy": "Pregnancy\u00a0avoid unless potential benefit outweighs risk"}, {"indications": "Indications\u00a0hypertension; migraine (section 4.7.4.2); menopausal flushing (section 6.4.1.1)", "name": "CLONIDINE HYDROCHLORIDE  - CENTRALLY ACTING ANTIHYPERTENSIVE DRUGS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.2 Centrally acting antihypertensive drugs"], "cautions": "Cautions\u00a0must be withdrawn gradually to avoid\r\nsevere rebound hypertension; mild to moderate\r\nbradyarrhythmia; constipation; polyneuropathy; Raynaud\u2019s\r\nsyndrome or other occlusive peripheral\r\nvascular disease; history of depression; interactions: Appendix 1 (clonidine)Driving\u00a0Drowsiness may affect performance\r\nof skilled tasks (e.g. driving); effects\r\nof alcohol may be enhanced", "side-effects": "Side-effects\u00a0constipation, nausea, dry mouth, vomiting, salivary\r\ngland pain, postural hypotension, dizziness, sleep disturbances, headache,\r\nmalaise, drowsiness, depression, sexual dysfunction, less\r\ncommonly bradycardia, Raynaud\u2019s syndrome, delusion, hallucination,\r\nparaesthesia, pruritus, rash, urticaria; rarely colonic\r\npseudo-obstruction, AV block, gynaecomastia, decreased lacrimation,\r\nnasal dryness, alopecia; also reported hepatitis,\r\nfluid retention, bradyarrhythmia, confusion, impaired visual accommodation", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2546.htm", "doses": ["By mouth, 50\u2013100\u00a0micrograms 3 times\r\ndaily, increased every second or third day; usual max. dose 1.2\u00a0mg\r\ndaily"], "pregnancy": "Pregnancy\u00a0may lower fetal heart rate, but risk should be balanced\r\nagainst risk of uncontrolled maternal hypertension; avoid intravenous\r\ninjection"}, {"indications": "Indications\u00a0prevention of recurrent migraine\r\n(but see notes above), vascular headache, menopausal flushing; hypertension\r\n(%s\n(From 2.5.2 Centrally acting antihypertensive drugs: British National Formulary)\n2.5.2 Centrally acting antihypertensive drugs)", "name": "CLONIDINE HYDROCHLORIDE  - CLONIDINE HYDROCHLORIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.4 Antimigraine drugs", "4.7.4.2 Prophylaxis of migraine", "CLONIDINE HYDROCHLORIDE"], "cautions": "Cautions\u00a0depressive illness; heart failure; Raynaud\u2019s syndrome; concurrent antihypertensive therapy; cerebrovascular disease; polyneuropathy; constipation; interactions: Appendix 1 (clonidine)", "side-effects": "Side-effects\u00a0constipation, dry mouth, nausea, vomiting; postural\r\nhypotension; depression, sleep disorder, dizziness, headache, drowsiness;\r\nerectile dysfunction; less commonly Raynaud\u2019s syndrome,\r\nparaesthesia, hallucination, rash, and pruritus; rarely AV block, gynaecomastia, and alopecia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3568.htm", "doses": ["adult over 18 years, 50\u00a0micrograms\r\ntwice daily, increased after 2 weeks to 75\u00a0micrograms twice daily\r\nif necessary"], "pregnancy": "Pregnancy\u00a0avoid unless potential benefit outweighs risk"}]